4.8 Article

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction A Multiorgan Roadmap

Journal

CIRCULATION
Volume 134, Issue 1, Pages 73-+

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCULATIONAHA.116.021884

Keywords

diastole; heart failure; heart failure, diastolic; phenotype; therapeutics; ventricular function, left

Funding

  1. National Institutes of Health [RO1 HL107577, RO1 HL127028]
  2. National Heart Lung and Blood Institute (NHLBI) Heart Failure Research Network [U10 HL110262-01]
  3. Aires Pharmaceuticals
  4. Medtronic
  5. Teva
  6. GSK
  7. National Institute of Health [R01AG18915, P30AG21332]
  8. Kermit Glenn Phillips II Chair in Cardiovascular Medicine
  9. European Commission [MEDIA-26140]
  10. CardioVasculair Onderzoek Nederland (CVON), Dutch Heart Foundation, The Netherlands (RECONNECT)
  11. NHLBI
  12. Veterans Administration
  13. Bayer
  14. CVRx
  15. Novartis
  16. CVON, Dutch Heart Foundation, The Netherlands (ARENA)
  17. CVON, Dutch Heart Foundation, The Netherlands (RECONNECT)
  18. CVON, Dutch Heart Foundation, The Netherlands (EARLY-HFPEF)
  19. [RO1 HL119012]
  20. [HL114910]

Ask authors/readers for more resources

Heart failure (HF) with preserved ejection fraction (EF; HFpEF) accounts for 50% of HF cases, and its prevalence relative to HF with reduced EF continues to rise. In contrast to HF with reduced EF, large trials testing neurohumoral inhibition in HFpEF failed to reach a positive outcome. This failure was recently attributed to distinct systemic and myocardial signaling in HFpEF and to diversity of HFpEF phenotypes. In this review, an HFpEF treatment strategy is proposed that addresses HFpEF-specific signaling and phenotypic diversity. In HFpEF, extracardiac comorbidities such as metabolic risk, arterial hypertension, and renal insufficiency drive left ventricular remodeling and dysfunction through systemic inflammation and coronary microvascular endothelial dysfunction. The latter affects left ventricular diastolic dysfunction through macrophage infiltration, resulting in interstitial fibrosis, and through altered paracrine signaling to cardiomyocytes, which become hypertrophied and stiff because of low nitric oxide and cyclic guanosine monophosphate. Systemic inflammation also affects other organs such as lungs, skeletal muscle, and kidneys, leading, respectively, to pulmonary hypertension, muscle weakness, and sodium retention. Individual steps of these signaling cascades can be targeted by specific interventions: metabolic risk by caloric restriction, systemic inflammation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exercise training, sodium retention by diuretics and monitoring devices, myocardial nitric oxide bioavailability by inorganic nitrate-nitrite, myocardial cyclic guanosine monophosphate content by neprilysin or phosphodiesterase 9 inhibition, and myocardial fibrosis by spironolactone. Because of phenotypic diversity in HFpEF, personalized therapeutic strategies are proposed, which are configured in a matrix with HFpEF presentations in the abscissa and HFpEF predispositions in the ordinate.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available